Linagliptin [orch, phsu]
Dipeptidyl Peptidase 4 Inhibitor [phsu]
Unique [qlco]
Pharmacological [bmod]
Profile [lbpr]
Efficacy [qlco]
Broad [spco]
Range [qnco]
Patients [podg]
Type 2 Diabetes [dsyn]
Introduction [hlca]
Increasing [ftcn]
Age [orga]
Obesity [dsyn]
Physical [hlca]
Inactive [qlco]
Diabetes Mellitus, Type 2 [dsyn]
Current Treatment [topp]
Limited [ftcn]
adverse events [fndg]
Drug drug interaction [moft]
Contraindication [qlco]
Need [qlco]
Dose Adjustment [hlca]
Patients [podg]
Renal Impairment [dsyn]
Covered [ftcn]
Paper [mnob]
reviews [inpr]
Study [mnob]
Evaluate [ftcn]
Pharmacokinetics [phsf]
pharmacodynamics [ftcn]
Efficacy [qlco]
Safety [hcpp]
Linagliptin [orch, phsu]
Dipeptidyl Peptidase 4 Inhibitor [phsu]
Recently [tmco]
Approved [qlco]
Japan [geoa]
Europe [geoa]
treatment [ftcn]
Diabetes Mellitus, Type 2 [dsyn]
Expert Opinion [cnce]
Oral [spco]
Linagliptin [orch, phsu]
mg% [qnco]
Daily [tmco]
effective [qlco]
Well [qlco]
Dipeptidyl Peptidase 4 Inhibitor [phsu]
Wide [spco]
Range [qnco]
Patients [podg]
Diabetes Mellitus, Type 2 [dsyn]
weight [orga]
Neutral [qlco]
Increasing [ftcn]
Hypoglycaemia [dsyn]
Administered [ftcn]
Alone [qnco]
Combination [qlco]
Diabetes [dsyn]
Treatments [topp]
Unique [qlco]
Pharmacological [bmod]
Profile [lbpr]
Class [inpr]
Dipeptidyl-Peptidase 4 Inhibitors [phsu]
Linagliptin [orch, phsu]
Dose Adjustment [hlca]
Patients [podg]
Renal Impairment [dsyn]
